A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
- Registration Number
- NCT01031225
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Brief Summary
This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 113
- Pathologically confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV NSCLC with measurable disease by RECIST and evidence of progression
- Availability of tissue for analysis
- ECOG Performance Status 0 or 1
- Adequate organ function as defined in the protocol.
- Must be at least 18 years old and able and willing to sign a written informed consent document
- Poor venous access requiring an indwelling catheter for study drug administration
- Women who are pregnant or lactating
- Ventricular ejection fraction < or = to 55% at baseline
- Any uncontrolled intercurrent illness
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 STA 9090 -
- Primary Outcome Measures
Name Time Method Progression Free Survival rate 16 weeks
- Secondary Outcome Measures
Name Time Method Safety and tolerability as measured by adverse event rates and laboratory evaluations 16 months Objective Response Rate, Disease Control Rate, Progression Free Survival, Overall Survival 18 months
Trial Locations
- Locations (21)
Arizona Cancer Center; University of Arizona
🇺🇸Tucson, Arizona, United States
City of Hope Medical Center
🇺🇸Duarte, California, United States
UCLA Health System
🇺🇸Santa Monica, California, United States
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Emory University- Winship Cancer Institute
🇺🇸Atlanta, Georgia, United States
University of Colorado Cancer Center
🇺🇸Aurora, Colorado, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
Oregon Health and Science University
🇺🇸Portland, Oregon, United States
Piedmont Hematology Oncology Associates
🇺🇸Winston Salem, North Carolina, United States
Swedish Medical Center
🇺🇸Seattle, Washington, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Vanderbilt-Ingram Cancer Center
🇺🇸Nashville, Tennessee, United States
Penn State Hershey Cancer Institute
🇺🇸Hershey, Pennsylvania, United States
University of North Carolina, Lineberger Comprehensive Cancer Center
🇺🇸Chapel Hill, North Carolina, United States
Nevada Cancer Institute
🇺🇸Las Vegas, Nevada, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Genesis Cancer Center
🇺🇸Hot Springs, Arkansas, United States